Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
Lung cancer is the leading cause of cancer-related deaths across the world, of which non-small cell lung cancer (NSCLC) accounts for 85%, and more than 50% of NSCLC patients were diagnosed with distant metastasis. The comprehensive treatment of NSCLC includes surgery, radiotherapy, chemotherapy, tar...
Guardado en:
Autores principales: | ZHU Kuikui, WU Gang |
---|---|
Formato: | article |
Lenguaje: | ZH |
Publicado: |
Magazine House of Cancer Research on Prevention and Treatment
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/285b3c127ca447da9782f43b0837486a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
por: Shijie Shang, et al.
Publicado: (2021) -
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
por: Alberto Bongiovanni, et al.
Publicado: (2021) -
Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021) -
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021)